Phase IIb trial of BIO 101 in patients with sarcopenic obesity

Trial Profile

Phase IIb trial of BIO 101 in patients with sarcopenic obesity

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Acronyms SARA INT; SARA-INT
  • Sponsors Biophytis
  • Most Recent Events

    • 04 Dec 2017 According to a Biophytis media release, now next steps will be to obtain regulatory approvals in France and in Italy, and the inclusion of the first patients in the United States and in Europe. Patients will be notably recruited from the group of sarcopenic patients followed in the SARA-OBS study, once their consent is obtained.
    • 04 Dec 2017 According to a Biophytis media release, this trial will be conducted in 20 clinical centers (among which those participating in the SARA-OBS study), in the EU (Belgium, France and Italy) and in the USA.
    • 04 Dec 2017 According to a Biophytis media release, Federal Agency for Medicines and Health Products (FAMHP) has approved this trial to conduct in Belgium, including the University Hospital of Liege.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top